Amgen Inc. (AMGN), headquartered in Thousand Oaks, California, is a pioneer in using technology and human genetic data to manufacture and develop innovative medicines. For more than 40 years, AMGN has been one of the leading players in using living cells to make biological medicines. Valued at $171.14 billion by market cap, it operates across diverse markets such as oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology, and neuroscience.
Shares of this biotechnology giant have outperformed the broader market considerably over the past year. AMGN has gained 40.21% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 28.9%. However, in 2024, AMGN’s stock rose 9.5%, lagging SPX’s 11.1% rise on a YTD basis.
